Biogen (NASDAQ:BIIB) is scheduled to release its earnings data before the market opens on Tuesday, April 24th. Analysts expect Biogen to post earnings of $5.89 per share for the quarter. Biogen has set its FY18 guidance at $24.20-25.20 EPS.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The company had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. During the same quarter last year, the business posted $5.04 EPS. Biogen’s quarterly revenue was up 15.1% compared to the same quarter last year. On average, analysts expect Biogen to post $25 EPS for the current fiscal year and $26 EPS for the next fiscal year.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ BIIB opened at $263.11 on Tuesday. Biogen has a fifty-two week low of $244.28 and a fifty-two week high of $370.57. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. The company has a market cap of $56,146.63, a price-to-earnings ratio of 12.06, a price-to-earnings-growth ratio of 1.46 and a beta of 0.86.

A number of equities research analysts have weighed in on BIIB shares. Credit Suisse Group upgraded Biogen from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $321.00 to $385.00 in a research note on Wednesday, December 20th. Nomura raised their price objective on Biogen from $355.00 to $420.00 and gave the company a “buy” rating in a research note on Saturday, December 30th. Robert W. Baird restated a “hold” rating on shares of Biogen in a research note on Thursday, January 25th. Citigroup restated an “outperform” rating and set a $380.00 price objective (up previously from $350.00) on shares of Biogen in a research note on Tuesday, January 16th. Finally, Canaccord Genuity set a $340.00 price objective on Biogen and gave the company a “hold” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and twenty-one have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $366.49.

In related news, EVP Alfred Sandrock sold 743 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $292.00, for a total value of $216,956.00. Following the sale, the executive vice president now owns 6,553 shares of the company’s stock, valued at approximately $1,913,476. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders sold 2,296 shares of company stock worth $678,993. Company insiders own 0.25% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Biogen (BIIB) Scheduled to Post Earnings on Tuesday” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Earnings History for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with's FREE daily email newsletter.